A scoping study is an economic evaluation of the project, and by putting interim in front of scoping study you really have to wonder what's going to be in it, probably more going to be like a pep talk. It's certainly not going to give you a resource upgrade, M&I only really comes into play at the feasibility stage anyway.
- Forums
- ASX - By Stock
- NVA
- General Chat
General Chat, page-2105
-
-
- There are more pages in this discussion • 5,786 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NVA (ASX) to my watchlist
|
|||||
Last
15.5¢ |
Change
0.025(19.2%) |
Mkt cap ! $37.75M |
Open | High | Low | Value | Volume |
14.0¢ | 16.0¢ | 13.5¢ | $20.43K | 141.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 972 | 14.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
15.5¢ | 12635 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 972 | 0.145 |
1 | 3000 | 0.140 |
2 | 24518 | 0.135 |
3 | 38461 | 0.130 |
1 | 5000 | 0.125 |
Price($) | Vol. | No. |
---|---|---|
0.155 | 12639 | 2 |
0.160 | 6678 | 3 |
0.165 | 30000 | 1 |
0.170 | 35000 | 1 |
0.175 | 50000 | 1 |
Last trade - 13.56pm 13/08/2024 (20 minute delay) ? |
Featured News
NVA (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online